Inhibition of Alpha Interferon (IFN-α)-Induced MicroRNA-122 Negatively Affects the Anti-Hepatitis B Virus Efficiency of IFN-α
暂无分享,去创建一个
Changfei Li | Saifeng Wang | Junli Hao | Hong-xia Fan | Lizhao Chen | S. Meng | B. Gao | Xiaojun Zhang | Xinghui Li | Guang-ze Liu | Wensong Jin
[1] L. Y. Wang,et al. Stable expression and integrated hepatitis B virus genome in a human hepatoma cell line. , 2012, Genetics and molecular research : GMR.
[2] G. Gao,et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1‐modulated P53 activity , 2012, Hepatology.
[3] K. Moore,et al. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. , 2011, Annual review of nutrition.
[4] Ling Zhang,et al. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. , 2011, Neoplasia.
[5] J. Ou,et al. Effects of Interferon-α/β on HBV Replication Determined by Viral Load , 2011, PLoS pathogens.
[6] A. Lohse,et al. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. , 2011, Gastroenterology.
[7] Angela M. Liu,et al. Two-tiered Approach Identifies a Network of Cancer and Liver Disease-related Genes Regulated by miR-122* , 2011, The Journal of Biological Chemistry.
[8] J. Bukh,et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1–6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR , 2011, Proceedings of the National Academy of Sciences.
[9] Jiming Zhang,et al. Indoleamine 2,3-Dioxygenase Mediates the Antiviral Effect of Gamma Interferon against Hepatitis B Virus in Human Hepatocyte-Derived Cells , 2010, Journal of Virology.
[10] Phillip A Sharp,et al. MicroRNA sponges: progress and possibilities. , 2010, RNA.
[11] Shi‐Mei Zhuang,et al. A novel GSK‐3 beta–C/EBP alpha–miR‐122–insulin‐like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma , 2010, Hepatology.
[12] X. Ye,et al. Rnai-mediated Downregulation of Upar Synergizes with Targeting of Her2 through the Erk Pathway in Breast Cancer Cells , 2022 .
[13] Hui Zhou,et al. Liver‐enriched transcription factors regulate MicroRNA‐122 that targets CUTL1 during liver development , 2010, Hepatology.
[14] C. Boucher,et al. Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.
[15] T. Liang,et al. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[16] Lipeng Qiu,et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. , 2010, Biochemical and biophysical research communications.
[17] Jinhong Chang,et al. Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus , 2010, Journal of Virology.
[18] M. Buendia,et al. Mechanisms of HBV-related hepatocarcinogenesis. , 2010, Journal of hepatology.
[19] B. Cullen,et al. MicroRNA Antagonism of the Picornaviral Life Cycle: Alternative Mechanisms of Interference , 2010, PLoS pathogens.
[20] S. Kauppinen,et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.
[21] E. Steyerberg,et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.
[22] K. Norman,et al. Modulation of Hepatitis C Virus RNA Abundance and the Isoprenoid Biosynthesis Pathway by MicroRNA miR-122 Involves Distinct Mechanisms , 2009, Journal of Virology.
[23] Krishna R. Kalari,et al. Cytosolic 5′-nucleotidase III (NT5C3): gene sequence variation and functional genomics , 2009, Pharmacogenetics and genomics.
[24] Lian-san Zhao,et al. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report , 2009, Virology Journal.
[25] Charles E. Vejnar,et al. Integration of microRNA miR-122 in hepatic circadian gene expression. , 2009, Genes & development.
[26] M. Torbenson,et al. Methylation regulates hepatitis B viral protein expression. , 2009, The Journal of infectious diseases.
[27] T. Asselah,et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.
[28] Lai Wei,et al. Role of ISGF3 in modulating the anti‐hepatitis B virus activity of interferon‐alpha in vitro , 2008, Journal of gastroenterology and hepatology.
[29] Dong-er Zhang,et al. The Level of Hepatitis B Virus Replication Is Not Affected by Protein ISG15 Modification but Is Reduced by Inhibition of UBP43 (USP18) Expression1 , 2008, The Journal of Immunology.
[30] Bryan R. G. Williams,et al. Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.
[31] H. Janssen,et al. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[32] D. Trono,et al. APOBEC3-Independent Interferon-Induced Viral Clearance in Hepatitis B Virus Transgenic Mice , 2008, Journal of Virology.
[33] A. Munnich,et al. miR-122, a paradigm for the role of microRNAs in the liver. , 2008, Journal of hepatology.
[34] Y. Okamoto,et al. Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. , 2007, Oncology reports.
[35] Xiaonan Zhang,et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. , 2007, The Journal of general virology.
[36] A. Kiss,et al. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[37] Stefano Volinia,et al. Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.
[38] H. Bonkovsky,et al. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. , 2007, Gastroenterology.
[39] Margaret S. Ebert,et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.
[40] D. Trono,et al. Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons , 2007, Journal of Virology.
[41] C. Croce,et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.
[42] N. Paran,et al. PGC-1α controls hepatitis B virus through nutritional signals , 2006, Proceedings of the National Academy of Sciences.
[43] Rongzhen Xu,et al. STAT1-Independent Cell Type-Specific Regulation of Antiviral APOBEC3G by IFN-α1 , 2006, The Journal of Immunology.
[44] S. Wain-Hobson,et al. Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication , 2006, Hepatology.
[45] R. Schinazi,et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.
[46] H. Tang,et al. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] R. Kawaguchi,et al. Quantitation of Hepatitis B Virus Genomic DNA by Real-Time Detection PCR , 1999, Journal of Clinical Microbiology.
[48] W. Filipowicz,et al. The liver-specific microRNA miR-122: biology and therapeutic potential. , 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[49] W. Filipowicz,et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.
[50] N. Paran,et al. PGC-1alpha controls hepatitis B virus through nutritional signals. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[51] A. Shiau,et al. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.